I agree with you. Xperience was approved in late April 2021. NXS can only proceed with those important trial runs (evidenced based-in recent investor briefing) that are needed to convince the surgeons only when xperience has been cleared by FDA. The trial runs have not even been completed.
Surely, Xperience can't be sold like pop corn without those trial runs to convince the surgeons.
Ann: Update on expected revenue for H1, page-16
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $56.88M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 20.0¢ | $1.907K | 9.516K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 11892 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 1470 | 1 |
View Market Depth
| Last trade - 12.49pm 05/07/2024 (20 minute delay) ? |
| NXS (ASX) Chart |